KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Common Equity (2016 - 2025)

Inovio Pharmaceuticals' Common Equity history spans 16 years, with the latest figure at -$7.7 million for Q3 2025.

  • For Q3 2025, Common Equity fell 110.5% year-over-year to -$7.7 million; the TTM value through Sep 2025 reached -$7.7 million, down 110.5%, while the annual FY2024 figure was $68.5 million, 41.62% down from the prior year.
  • Common Equity for Q3 2025 was -$7.7 million at Inovio Pharmaceuticals, down from $28.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $581.6 million in Q1 2021 and bottomed at -$7.7 million in Q3 2025.
  • The 5-year median for Common Equity is $169.4 million (2023), against an average of $216.6 million.
  • The largest annual shift saw Common Equity soared 209.61% in 2021 before it tumbled 110.5% in 2025.
  • A 5-year view of Common Equity shows it stood at $399.7 million in 2021, then crashed by 44.36% to $222.4 million in 2022, then plummeted by 47.23% to $117.3 million in 2023, then plummeted by 41.62% to $68.5 million in 2024, then tumbled by 111.27% to -$7.7 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Common Equity are -$7.7 million (Q3 2025), $28.5 million (Q2 2025), and $51.3 million (Q1 2025).